Study · Animal study (in vivo) · 2007
5 resultsBuzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, Thompson CB
Cancer research1 Jul 2007Cited by 735 (Europe PMC)
The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)
Text rights: Publisher copyright. Results still quote short attributed sentences.
5 results from studies that gave the peptide. No result from this study comes from people.
In vivo, AICAR selectively inhibited p53-deficient tumor growth.
In plain wordsIn animals, AICAR selectively reduced growth of tumors without p53.
n: not reported in source
HCT116 p53-deficient tumor xenograftsSource sentences
Treatment with AICAR, another AMPK activator, also showed a selective ability to inhibit p53(-/-) tumor growth in vivo.
In HCT116 cells exposed to AICAR, p53-positive cells activated autophagy, but p53-deficient cells did not.
In plain wordsIn cells given AICAR, cells with p53 activated autophagy, but cells without p53 did not.
n: not reported in source
HCT116 p53-positive and p53-deficient colon cancer cellsSource sentences
In the presence of either of the two drugs, HCT116 p53(+/+) cells, but not HCT116 p53(-/-) cells, activated autophagy.
Treatment with AICAR, another AMPK activator, also showed a selective ability to inhibit p53(-/-) tumor growth in vivo.
In nontransformed mouse embryo fibroblasts, AICAR induced autophagy in a p53-dependent manner.
In plain wordsIn cells from mouse embryos, AICAR-induced autophagy depended on p53.
mousen: not reported in source
Nontransformed mouse embryo fibroblastsSource sentences
A similar p53-dependent induction of autophagy was observed when nontransformed mouse embryo fibroblasts were treated.
In the presence of either of the two drugs, HCT116 p53(+/+) cells, but not HCT116 p53(-/-) cells, activated autophagy.
In mouse embryo fibroblasts, AICAR enhanced fatty acid beta-oxidation in p53-positive cells, but not p53-deficient cells.
In plain wordsIn mouse cells, AICAR increased fatty acid burning in cells with p53, but not cells without p53.
mousen: not reported in source
Mouse embryo fibroblastsSource sentences
Treatment with either metformin or AICAR also led to enhanced fatty acid beta-oxidation in p53(+/+) MEFs, but not in p53(-/-) MEFs.
In p53-positive mouse embryo fibroblasts, AICAR induced more fatty acid beta-oxidation than metformin.
In plain wordsIn mouse cells with p53, AICAR increased fatty acid burning more than metformin.
mousen: not reported in source
p53(+/+) mouse embryo fibroblastsSource sentences
However, the magnitude of induction was significantly lower in metformin-treated cells, as metformin treatment also suppressed mitochondrial electron transport.
Treatment with either metformin or AICAR also led to enhanced fatty acid beta-oxidation in p53(+/+) MEFs, but not in p53(-/-) MEFs.
AI wrote and checked these results. AI can make mistakes, so check important results against the source.
PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.
Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC
Terms as the source lists them.
PepBank is a research reference. Talk to a doctor before you use any peptide.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated